GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aldeyra Therapeutics Inc (FRA:137) » Definitions » Shiller PE Ratio

Aldeyra Therapeutics (FRA:137) Shiller PE Ratio : (As of Jan. 19, 2025)


View and export this data going back to 2021. Start your Free Trial

What is Aldeyra Therapeutics Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Aldeyra Therapeutics Shiller PE Ratio Historical Data

The historical data trend for Aldeyra Therapeutics's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aldeyra Therapeutics Shiller PE Ratio Chart

Aldeyra Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Aldeyra Therapeutics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Aldeyra Therapeutics's Shiller PE Ratio

For the Biotechnology subindustry, Aldeyra Therapeutics's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Aldeyra Therapeutics's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Aldeyra Therapeutics's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Aldeyra Therapeutics's Shiller PE Ratio falls into.



Aldeyra Therapeutics Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Aldeyra Therapeutics's E10 for the quarter that ended in Sep. 2024 is calculated as:

For example, Aldeyra Therapeutics's adjusted earnings per share data for the three months ended in Sep. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Sep. 2024 (Change)*Current CPI (Sep. 2024)
=-0.225/133.0289*133.0289
=-0.225

Current CPI (Sep. 2024) = 133.0289.

Aldeyra Therapeutics Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201412 -0.243 99.070 -0.326
201503 -0.296 99.621 -0.395
201506 -0.241 100.684 -0.318
201509 -0.312 100.392 -0.413
201512 -0.422 99.792 -0.563
201603 -0.458 100.470 -0.606
201606 -0.365 101.688 -0.477
201609 -0.339 101.861 -0.443
201612 -0.351 101.863 -0.458
201703 -0.346 102.862 -0.447
201706 -0.312 103.349 -0.402
201709 -0.268 104.136 -0.342
201712 -0.304 104.011 -0.389
201803 -0.349 105.290 -0.441
201806 -0.394 106.317 -0.493
201809 -0.446 106.507 -0.557
201812 -0.343 105.998 -0.430
201903 -0.513 107.251 -0.636
201906 -0.434 108.070 -0.534
201909 -0.627 108.329 -0.770
201912 -0.423 108.420 -0.519
202003 -0.308 108.902 -0.376
202006 -0.222 108.767 -0.272
202009 -0.195 109.815 -0.236
202012 -0.247 109.897 -0.299
202103 -0.210 111.754 -0.250
202106 -0.232 114.631 -0.269
202109 -0.230 115.734 -0.264
202112 -0.239 117.630 -0.270
202203 -0.263 121.301 -0.288
202206 -0.284 125.017 -0.302
202209 -0.253 125.227 -0.269
202212 -0.208 125.222 -0.221
202303 -0.252 127.348 -0.263
202306 -0.138 128.729 -0.143
202309 -0.131 129.860 -0.134
202312 -0.073 129.419 -0.075
202403 -0.129 131.776 -0.130
202406 -0.260 132.554 -0.261
202409 -0.225 133.029 -0.225

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Aldeyra Therapeutics  (FRA:137) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Aldeyra Therapeutics Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Aldeyra Therapeutics's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Aldeyra Therapeutics Business Description

Traded in Other Exchanges
Address
131 Hartwell Avenue, Suite 320, Lexington, MA, USA, 02421
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases. The company's product candidate, reproxalap, is a first-in-class treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer.

Aldeyra Therapeutics Headlines

No Headlines